On October 7, 2020 Pacira BioSciences, Inc. (Nasdaq: PCRX), the leading provider of innovative non-opioid pain management options, reported preliminary unaudited net product sales of EXPAREL (bupivacaine liposome injectable suspension) and iovera° of $113.7 million and $2.7 million, respectively, for the third quarter of 2020 (Press release, Pacira Pharmaceuticals, OCT 7, 2020, View Source [SID1234568185]). The company also reported preliminary unaudited net product sales of EXPAREL and iovera° of $39.5 million and $1.1 million, respectively, for the month of September 2020. EXPAREL average daily sales were 109 percent, 111 percent, and 110 percent of prior year levels for the months of July, August, and September, respectively.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are very encouraged with our strong performance as revenue and claims data show EXPAREL weekly growth rates exceeding those of the elective surgery market due to its expanding role in shifting a variety of complex surgical procedures to the 23-hour stay environment and broadening utilization in non-elective procedures, such as cesarean sections, cardiothoracic and oncology surgeries. When the elective surgery market recovers to its normal pace, we expect EXPAREL revenue to experience further growth," said Dave Stack, chairman and chief executive officer of Pacira BioSciences. "Demand for training around nerve and field blocks continues to grow and we remain on track to launch our state-of-the-art Innovation and Training Center in Tampa later this month. This facility will advance interactive, hands-on instruction around best practice field block techniques while improving patient care and enabling patient migration to the 23-hour stay environment."
During the second quarter of 2020, the company’s product sales were negatively impacted by the COVID-19 pandemic, which mandated significant postponement or suspension in the scheduling of elective surgical procedures resulting from public health guidance and government directives. Elective surgery restrictions began to lift on a state-by-state basis in April 2020. In order to provide greater transparency, the company will continue to report monthly intra-quarter unaudited net product sales until it has gained enough visibility around the impacts of COVID-19. The financial information included in this press release is preliminary, unaudited and subject to adjustment. It does not present all information necessary for an understanding of the company’s financial results for the third quarter or full year 2020.